

## Pharnext announces reclassification of its historical investor's shares, strengthening the position of core shareholders

PARIS, France, 5.45pm, 29 March, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, was informed of a reclassification of its historical investor's shares.

2,143,736 shares held by Truffle Capital, co-founder of Pharnext, and representing 19.9% ownership of the company, have just been reclassified to existing shareholders including two core shareholders: Pierre Bastid (+600,000 shares) and Claude Berda (+1,243,736 shares). Truffle Capital states that the funds selling the shares are mutual investment funds that have reached maturity and therefore had a regulatory obligation to exit from their investments and, that other recent funds invested in Pharnext's Initial Public Offering in July 2016.

The initial lock-up commitments relating to the shares have been assumed in full by their new owners.

After such reclassification, new ownership of Pharnext's shares and voting rights are as follows:

	Shares	%	Voting rights	%
<b>Founders and employees</b>	1,318,084	12.2%	2,617,684	17.8%
<b>Pierre Bastid (Zaka)</b>	2,542,301	23.6%	3,267,901	22.3%
<b>Claude Berda (CBLux)</b>	1,632,688	15.1%	1,632,688	11.1%
<b>Truffle Capital</b>	1,119,410	10.4%	1,419,010	9.7%
<b>Industrials (Galapagos, Ipsen, Mérieux, Dassault)</b>	694,021	6.4%	856,621	5.8%
<b>Public (institutionnals and individuals)</b>	3,486,111	32.3%	4,891,511	33.3%
<b>TOTAL</b>	<b>10,792,615</b>		<b>14,685,415</b>	

## PHARNEXT | THE NEXT MEDICINE

### About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several compositions of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, please visit [www.pharnext.com](http://www.pharnext.com)

### CONTACTS:

#### Pharnext

Pierre Schwich  
Chief Financial Officer  
[investors@pharnext.com](mailto:investors@pharnext.com)  
+33 (0)1 41 09 22 30

#### Investor Relations (Europe)

MC Services AG  
Anne Hennecke  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)  
+49 211 529252 22

#### Media Relations (Europe)

ALIZE RP  
Caroline Carmagnol  
Margaux Pronost  
[pharnext@alizerp.com](mailto:pharnext@alizerp.com)  
+33 (0)1 44 54 36 64

#### Investor Relations (U.S.)

Stern Investor Relations, Inc.  
Sarah McCabe  
[sarah@sternir.com](mailto:sarah@sternir.com)  
+1 212-362-1200

#### Media Relations (U.S.)

Russo Partners  
Tony Russo, Ph.D.  
Victoria Meissner, M.D.  
[tony.russo@russopartnersllc.com](mailto:tony.russo@russopartnersllc.com)  
[victoria.meissner@russopartnersllc.com](mailto:victoria.meissner@russopartnersllc.com)  
+1 212-845-4251  
+1 646-942-5627

#### Investor Relations (France)

NewCap  
Julie Coulot  
[pharnext@newcap.eu](mailto:pharnext@newcap.eu)  
+33 (0)1 44 71 20 40